[1]JournalofMedicinalChemistry,2008,vol.51,p.2412-2420
[2]Patent:WO2016/11195,2016,A1.Locationinpatent:Paragraph0053;0103
[1]CurrentPatentAssignee:IMMUNOGENESISINC-WO2016/11195,2016,A1
[1]ACSMedicinalChemistryLetters,2017,vol.8,p.1269-1274
[1]Patent:CN110746459,2020,A.Locationinpatent:Paragraph0039;0056-0061
Title: Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20150501
Title: Metabolism and excretion of TH-302 in dogs.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20120701
Title: TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Journal: Cancer chemotherapy and pharmacology 20120601
Title: Metabolism, pharmacokinetics and excretion of a novel hypoxia activated cytotoxic prodrug, TH-302, in rats.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20120401
Title: Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys.
Journal: Cancer chemotherapy and pharmacology 20120301
Title: Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302.
Journal: Molecular cancer therapeutics 20120301
Title: Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120201
Title: Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20110501
Title: Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.
Journal: Blood 20100902
Title: Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Journal: Biological trace element research 20100901
Title: Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs.
Journal: Journal of medicinal chemistry 20080424
Title: Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422.
Title: Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289.
Title: Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment 8FHX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92.